gilead sciences
Dr. Reddy’s releases COVID drug Remdesivir under brand name Redyx
"Dr Reddy's Redyx is available in strength of 100 mg vial," it said
India's cheapest remdesivir version launched by Zydus Cadila at Rs 2,800 per vial
The drug will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients
Gilead starts testing inhaled version of remdesivir for COVID-19
Gilead also plans to start additional clinical trials to evaluate remdesivir when used in combination with anti-inflammatory medicines
Mylan Pharma to launch remdesivir in India at Rs 4,800 per 100 mg vial
The drug will be launched under the brand name Desrem in India and will be available to patients later this month
Remdesivir gets conditional EU clearance to be used in severe COVID-19 patients
The move comes just days after Gilead allocated nearly all of its supply of remdesivir for the next three months to the US
Gilead Sciences to start trials of inhaled version of remdesivir
The FDA granted remdesivir an emergency use authorisation for the treatment of hospitalised patients with severe Covid-19
Health ministry okays remdesivir for moderate cases, HCQ for early course of COVID-19
It also okayed off-label application of tocilizumab, a drug that modifies the immune system or its functioning, and convalescent plasma
AstraZeneca approaches Gilead about potential merger
Gilead, AstraZeneca and several other drugmakers are racing to develop vaccines for COVID-19
India's drug regulator grants Gilead Sciences marketing authorisation for remdesivir
The approval process for remdesivir was accelerated in view of emergency situation and unmet need for medicines in light of covid19 outbreak
Gilead ties up with 5 generic drugmakers in India, Pakistan for Covid19 drug supply
The licenses are royalty-free until the World Health Organization declares the end of the public health emergency regarding Covid-19